Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022020945 - ANTI-CD22 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC CONSTRUCTS

Publication Number WO/2022/020945
Publication Date 03.02.2022
International Application No. PCT/CA2021/051046
International Filing Date 27.07.2021
IPC
C07K 16/22 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors
A61K 35/17 2015.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
A61P 37/06 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
06Immunosuppressants, e.g. drugs for graft rejection
CPC
A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
A61P 37/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
06Immunosuppressants, e.g. drugs for graft rejection
C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
Applicants
  • NATIONAL RESEARCH COUNCIL OF CANADA [CA]/[CA]
Inventors
  • MCCOMB, Scott
  • WEERATNA, Risini
  • ARBABI-GHAHROUDI, Mehdi
  • NGUYEN, Tina
  • WU, Cunle
Agents
  • BOOCOCK, Graeme R.
  • VICKERS, Mark F.
  • DYBWAD, Scott
  • DAMIANI, Michael
  • ALLARD, Louis
  • KEELER, Todd
  • EVENSON, Brandon
  • BEHMANN, Curtis B.
  • DE KLEINE, Geoffrey
  • MARSMAN, Kathleen E.
  • NAUMAN, David A.
  • PUNDSACK, Scott
  • COGHLAN, Jeffrey
  • GORDON, Jeff
  • RAOUL, Jennifer
  • SOJONKY, Andrew D.
  • WEBB, Timothy
  • MUELLER-NEUHAUS, Jason R.
  • SKINNER, Mhairi
  • LITTLE, Vanessa Renee
Priority Data
63/058,20329.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) ANTI-CD22 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC CONSTRUCTS
(FR) ANTICORPS ANTI-CD22 À DOMAINE UNIQUE ET CONSTRUCTIONS THÉRAPEUTIQUES
Abstract
(EN) Herein are provided anti-CD22 single domain antibodies (sdAb) prepared by immunizing a llama with the extracellular domain of the predominant human CD22 isoform. By constructing a library of the heavy chain repertoire generated, VHH antibodies specific to the immunogen were isolated. The 27 example antibodies initially produced comprise CDR1, CDR2, and CDR3 sequences corresponding, respectively to SEQNOs: 1-3, 4-6, 7-9, 10-12, 13-15, 16- 18, 19-21, 22-24, 25-27, 28-30, 31-33, 34-36, 37-39, 40-42, 43-45, 46-48, 49-51, 52-54, 55- 57, 58-60, 61-63, 64-66, 67-69, 70-72, 73-75, 75-78, and 79-81; and related sequences. Also provided are multivalent antibodies comprising any one of the sdAbs, including bispecific T-cell engagers, bispecific killer cell engagers (BiKEs), and trispecific killer cell engagers (TriKEs). Also described are chimeric antigen receptors (CARs) for CAR-T therapy comprising any one of the aforementioned sdAbs. Uses of these molecules in the treatment of cancer are also described.
(FR) La présente invention concerne des anticorps anti-CD22 à domaine unique (sdAb) préparés par immunisation d'un lama avec le domaine extracellulaire de l'isoforme de CD22 humain majoritaire. En construisant une banque du répertoire de chaînes lourdes généré, des anticorps VHH spécifiques de l'immunogène ont été isolés. Les 27 exemples d'anticorps produits initialement comprennent les séquences CDR1, CDR2 et CDR3 correspondant respectivement aux SEQ ID NO : 1-3, 4-6, 7-9, 10-12, 13-15, 16- 18, 19-21, 22-24, 25-27, 28-30, 31-33, 34-36, 37-39, 40-42, 43-45, 46-48, 49-51, 52-54, 55- 57, 58-60, 61-63, 64-66, 67-69, 70-72, 73-75, 75-78, et 79-81 ; et séquences associées. L'invention concerne également des anticorps multivalents comprenant l'un quelconque des sdAbs, comprenant des engageurs de lymphocytes T bispécifiques, des engageurs de cellules tueuses bispécifiques (BiKEs) et des engageurs de cellules tueuses trispécifiques (TriKEs). L'invention concerne également des récepteurs antigéniques chimériques (CAR) pour une thérapie CAR-T comprenant l'un quelconque des sdAbs mentionnés ci-dessus. L'invention concerne également des utilisations de ces molécules dans le traitement du cancer.
Latest bibliographic data on file with the International Bureau